PAR-25-128: Biology of Bladder Cancer (R21 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants of up to $200,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make $200,000 in total. Applications closed on September 7, 2025.
From the official notice on Grants.gov, last changed November 20, 2024. Checked November 7, 2026.
- Award ceiling$200,000
- Total funding$200,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR21
- Clinical trialsOptional
- Funded byNCI
- Median yearly award$412,856
- Typical project length2 years
- R21, Exploratory/Developmental Research Grant. Early, exploratory ideas that may not have preliminary data yet, usually for up to two years. Other open R21 notices.
Projects funded under PAR-25-128 were run by National Cancer Institute (NCI, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-25-128 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-22-219 | July 26, 2022 | Closed November 19, 2024 | Closed |
Key dates
| Posted | November 19, 2024 |
|---|---|
| Deadline | September 7, 2025 |
| Archived by Grants.gov | October 13, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $412,856; it allows up to $200,000 per award.
- Most of the program's money (66% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.
Funded under PAR-25-128 so far
NIH funded 1 project under PAR-25-128 in fiscal 2026, at 1 institution. The median yearly award was $412,856.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Investigating the role of cell cycle plasticity in the growth and progression of bladder cancers | University of Pittsburgh at Pittsburgh | 2026 | $412,856 |
Who has won Cancer Cause and Prevention Research grants before
From fiscal 2021 to 2025, Cancer Cause and Prevention Research (93.393) awarded $3.6 billion across 2,517 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 81 | $107 million |
| Sloan-Kettering Institute for Cancer Research | New York | 65 | $99.1 million |
| The Trustees of Columbia University in the City of New York | New York | 48 | $85.3 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 51 | $83.1 million |
| University of North Carolina at Chapel Hill | North Carolina | 49 | $76.1 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-25-128 still open?
No. It closed on September 7, 2025.
Who can apply for Biology of Bladder Cancer (R21 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Biology of Bladder Cancer (R21 Clinical Trial Optional)?
Closed September 7, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $200,000 each. About $200,000 in total.
Who has been funded under PAR-25-128?
NIH RePORTER lists 1 project funded under PAR-25-128 in fiscal 2026, at 1 institution.
Who has won Cancer Cause and Prevention Research grants before?
The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York. The program made 2,517 awards worth $3.6 billion in that time.
Similar open grants
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
- Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
- Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
- New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)
- Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)